Estrogenic Regulation of Mitochondrial Transcription in Huntington's Disease
Project Number5R01NS052724-03
Contact PI/Project LeaderRYU, HOON
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (provided by applicant): While the role of mitochondrial dysfunction has been proposed in neurodegenerative diseases, the exact mechanism of mitochondrial pathogenesis is unclear. Our preliminary studies show that hormone receptors, estrogen receptors (ERs), and cAMP response elements binding protein (CREB) are present in the mitochondrial matrix of neurons. CREB directly binds to cAMP response elements (CREs) in the promoter regions (D-loop) of mitochondrial DNA. We also show that CREB is transcriptionally active in mitochondria and hypothesize that the regulation of mitochondrial gene expression by mitochondrial CREB may underlie some of the established protective effects in neuronal survival. This data implies that mitochondrial localization of ERs and CREB could be regulated by novel signaling pathways in the intact central nervous system and that their functions in the mitochondria might be important in neuronal survival. Therefore, we propose that the levels and activities of mitochondrial hormone receptors and transcription factors, which induce mitochondrial gene transactivation, may contribute to mitochondrial dysfunction and the subsequent neuronal loss observed in Huntington's disease (HD). Thus, the specific aims of our proposed study are: 1) To identify the topographic brain distribution of mitochondrial ERs and characterize mitochondrial estrogen receptor element (ERE) sites and interaction with CREB in neurons. 2) To determine the regulatory mechanism of mitochondrial ERs and CREB-mediated mitochondrial transcription. Protein Kinase A (PKA) is a well known enzyme for activation of ERs and phosphorylating CREB at Ser133. In this context, we propose that PKA localizes into the mitochondrial matrix and that mitochondrial PKA activity may play a role in the phosphorylation and transactivation of mitochondrial ERs and CREB. We will further characterize mitochondrial ER, PKA, and CREB activity in mouse models of HD. 3) To develop therapeutic approaches to target mitochondrial ERs and CREB in vitro and in vivo in transgenic and Knock-in HD mice expressing short segment and full length mutant huntingtin. We will determine whether specific estrogen receptor modulators (SERMs) augment mitochondrial PKA activity and mitochondrial ER and CREB phosphorylation to induce mitochondrial gene transcription that influences neuronal survival. These studies will provide novel mechanisms for preventing mitochondrial transcriptional dysfunction and help in the design of applicable compounds that modulate mitochondrial function.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
15-July-2005
Project End Date
31-March-2010
Budget Start Date
01-April-2007
Budget End Date
31-March-2008
Project Funding Information for 2007
Total Funding
$248,648
Direct Costs
$197,340
Indirect Costs
$51,308
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Neurological Disorders and Stroke
$248,648
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS052724-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS052724-03
Patents
No Patents information available for 5R01NS052724-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS052724-03
Clinical Studies
No Clinical Studies information available for 5R01NS052724-03
News and More
Related News Releases
No news release information available for 5R01NS052724-03
History
No Historical information available for 5R01NS052724-03
Similar Projects
No Similar Projects information available for 5R01NS052724-03